A pharmacogenomic method for individualized prediction of drug sensitivity

作者：Cohen Adam L; Soldi Raffaella; Zhang Haiyu; Gustafson Adam M; Wilcox Ryan; Welm Bryan E; Chang Jeffrey T; Johnson Evan; Spira Avrum; Jeffrey Stefanie S^*; Bild Andrea H

来源：Molecular Systems Biology, 2011, 7(1): 513.

DOI：10.1038/msb.2011.47

• biomarkers
• cancer
• pharmacogenomics

Identifying the best drug for each cancer patient requires an efficient individualized strategy. We present MATCH (Merging genomic and pharmacologic Analyses for Therapy CHoice), an approach using public genomic resources and drug testing of fresh tumor samples to link drugs to patients. Valproic acid (VPA) is highlighted as a proof-of-principle. In order to predict specific tumor types with high probability of drug sensitivity, we create drug response signatures using publically available gene expression data and assess sensitivity in a data set of >40 cancer types. Next, we evaluate drug sensitivity in matched tumor and normal tissue and exclude cancer types that are no more sensitive than normal tissue. From these analyses, breast tumors are predicted to be sensitive to VPA. A meta-analysis across breast cancer data sets shows that aggressive subtypes are most likely to be sensitive to VPA, but all subtypes have sensitive tumors. MATCH predictions correlate significantly with growth inhibition in cancer cell lines and three-dimensional cultures of fresh tumor samples. MATCH accurately predicts reduction in tumor growth rate following VPA treatment in patient tumor xenografts. MATCH uses genomic analysis with in vitro testing of patient tumors to select optimal drug regimens before clinical trial initiation. Molecular Systems Biology 7: 513; published online 19 July 2011; doi:10.1038/msb.2011.47

• 出版日期2011-7